We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

113 hedge funds and large institutions have $262M invested in BioSpecifics Technologies Corp. in 2020 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 54 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 12

1% more funds holding

Funds holding: 112113 (+1)

0% less capital invested

Capital invested by funds: $263M → $262M (-$1.18M)

54% less repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 54

Holders
113
Holders Change
+1
Holders Change %
+0.89%
% of All Funds
2.49%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
15
Increased
25
Reduced
54
Closed
12
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Deutsche Bank
76
Deutsche Bank
Germany
$221K +$13.8K +243 +7%
Bessemer Group
77
Bessemer Group
New Jersey
$221K +$223K +3,911 New
JMPWA
78
JP Morgan Private Wealth Advisors
California
$209K -$5.07K -89 -2%
AIG
79
American International Group
New York
$205K -$11.9K -209 -5%
SI
80
Shaker Investments
Ohio
$201K +$203K +3,555 New
MIM
81
MetLife Investment Management
New Jersey
$172K
Bank of America
82
Bank of America
North Carolina
$168K -$31.6K -555 -16%
DA
83
Denali Advisors
California
$164K -$2.34K -41 -1%
Macquarie Group
84
Macquarie Group
Australia
$158K
MF
85
Manchester Financial
California
$147K -$200K -3,510 -57%
SG Americas Securities
86
SG Americas Securities
New York
$124K +$125K +2,194 New
MLICM
87
Metropolitan Life Insurance Company (MetLife)
New York
$119K
Barclays
88
Barclays
United Kingdom
$115K -$234K -4,100 -67%
BNP Paribas Financial Markets
89
BNP Paribas Financial Markets
France
$108K +$55.8K +980 +106%
Citigroup
90
Citigroup
New York
$104K +$29.2K +513 +39%
OSAM
91
O'Shaughnessy Asset Management
Connecticut
$95K +$89.5K +1,571 +1,689%
MAM
92
Meeder Asset Management
Ohio
$92K +$52.7K +924 +131%
Legal & General Group
93
Legal & General Group
United Kingdom
$71K -$16.7K -293 -18%
GT
94
Glenmede Trust
Pennsylvania
$67K
APA
95
American Portfolios Advisors
New York
$60.9K
FANJ
96
Financial Architects (New Jersey)
New Jersey
$51K
ASN
97
Advisory Services Network
Georgia
$44K +$44.2K +775 New
BFEC
98
Benjamin F. Edwards & Company
Missouri
$38K +$18.2K +320 +92%
US Bancorp
99
US Bancorp
Minnesota
$37K -$17K -299 -32%
AIP
100
Ameritas Investment Partners
Nebraska
$28K

BSTC Hedge Fund Activity: Q1 2020 in Review

113 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q1 2020, worth a combined $262M — down 0.45% from $263M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new BSTC positions and 12 closed out — a net gain of 3 holders — while 25 added to existing stakes and 54 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $15.6M. The largest seller was Allianz Asset Management, cutting an estimated $2.97M.

  • 113 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q1 2020, up from 112 in Q4 2019.
  • Funds reported $262M of BioSpecifics Technologies Corp. stock for Q1 2020, down 0.45% quarter-over-quarter.
  • 15 funds opened new BioSpecifics Technologies Corp. positions in Q1 2020 and 12 closed out, a net change of +3 holders.
  • The largest BioSpecifics Technologies Corp. buyer in Q1 2020 was Janus Henderson Group, an estimated $15.6M added.
  • The largest BioSpecifics Technologies Corp. seller in Q1 2020 was Allianz Asset Management, an estimated $2.97M sold.

Based on aggregated 13F filings for Q1 2020.